Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion.
Invasive fungal infections are serious complications of cancer therapy. We present a case report of a 12-year-old boy diagnosed with abdominal non-Hodgkin lymphoma and fecal and Candida peritonitis during induction chemotherapy. The invasive mycosis was managed using a combined approach of systemic antifungal agents including efungumab and surgical interventions. Efungumab, a recombinant antibody that inhibits extracellular heat shock protein 90, was used in combination with amphotericin B colloid dispersion after the failure of standard approaches.
Krenova
Zdenka
Z
Departments of Pediatric Oncology, University Hospital Brno, Czech Republic. zkrenova@fnbrno.cz
Pavelka
Zdenek
Z
Lokaj
Petr
P
Skotakova
Jarmila
J
Kocmanova
Ivana
I
Teyschl
Otakar
O
Kren
Leos
L
Mudry
Peter
P
Sterba
Jaroslav
J
D000008:Abdominal Neoplasms / Q000150:complications* / Q000188:drug therapy; D000666:Amphotericin B / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents / Q000008:administration & dosage*; D002177:Candidiasis / Q000188:drug therapy*; D002648:Child; D004359:Drug Therapy, Combination; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008297:Male; D010538:Peritonitis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D018841:HSP90 Heat-Shock Proteins; D000666:Amphotericin B; C512268:efungumab